Please login to the form below

BeiGene

This page shows the latest BeiGene news and features for those working in and with pharma, biotech and healthcare.

China’s BeiGene raises $903m from Hong Kong IPO

BeiGene recently said it had completed enrolment in a phase III trial of zanubrutinib in Waldenström macroglobulinemia and could file for approval in the US in mid-2019. ... BeiGene’s shares are expected to begin trading on the HKEX on 8 August under

Latest news

Daily Brief: Biosimilars ready to pounce on Humira, Hong Kong could rival Nasdaq, Kymab's OX40 candidate

Read the NHS' internal briefing on adalimumab biosimilars from May. Hong Kong could be new biotech hub, says Beigene, heading for $1bn floatation. ... A total of eight companies in biotech research have filed since May, and now Beigene is planning the
Keytruda is first I-O drug cleared for melanoma in China

China’s pharma industry isn’t resting on its laurels, however, and Beijing company BeiGene said earlier this week it plans to file for approval of its PD-1 inhibitor tislelizumab
China’s BeiGene takes PD-1 antibody into pivotal trials

Along with BeiGene, Hengrui Medicine also has an anti-PD-1 drug in registration trials, and there are upwards of 20 other PD-1 and PD-L1 drugs in earlier clinical ... Not all of BeiGene’s programmes are directed solely to the Chinese market.
Celgene joins PD-1 race via partnership with BeiGene

Celgene's push into immuno-oncology has continued with a $1.4bn agreement to license ex-Asian rights to BeiGene's PD-1 inhibitor BGB-A317, including $263m upfront. ... Under the terms of the deal Celgene takes a $150m stake in BeiGene, giving it a bigger
Merck KGaA to research cancer drug with Chinese biotech

The compound, currently known as BeiGene-283, is a second-generation BRAF inhibitor and is expected to enter clinical development in 2014. ... The agreement sees Merck pay BeiGene an undisclosed upfront fee as well as several clinical and commercial

More from news
Approximately 5 fully matching, plus 1 partially matching documents found.

Latest Intelligence

Chinese biotech’s global ambitions

BeiGene says it as headed off any such concens by working with well-established pharma company and contract manufacturer Boehringer Ingelheim to manufacture its drug. ... Meanwhile, BeiGene is also looking to break into the still all-important US market.
Biopharma's Future: Made in China

The rise of Chinese biopharma. One home-grown pharma company which could replicate this accomplishment is Beijing-headquartered BeiGene. ... BeiGene’s CEO John Oyler told a Goldman Sachs recent conference that a Chinese biopharma sector was ready to
Deal Watch March 2017

In particular, the third largest deal of the month is a joint venture between the research-based biotechnology company, BeiGene, which focuses on immuno-oncology, and the Guangzhou Development District. ... The agreement, worth $330m, will build BeiGene
Deal Watch table for November 2013

BeiGene / Merck. Serono. Co-development. Expansion of collaboration to include BeiGene 290 for cancer.

More from intelligence
Approximately 2 fully matching, plus 2 partially matching documents found.

Featured jobs

Senior Account Director development role to Business Director, H...: Excellent package

Associate Director: £75, 000-90, 000

Editorial Assistant Medical Education Agency: £25, 000 - £26, 000

Account Director, Healthcare Marketing Agency: Salary TBC

Account Manager / Senior Account Manager: 35, 000-40, 000

Account Director – Health Policy – Global Agency: Salary TBC

Account Director, Medical Education: Salary TBC

Senior Medical Writer: Salary TBC

Account Director – Healthcare Marketing – Berks: Salary TBC

Technical Manager – Developer and Commercial Excellence, Healthc...: Excellent package

Medical Writer: Salary TBC

Account Director: Competitive Salary Offered

Global Business Development Director – Health Education: excellent commission

Client Services Director – Medical Education Agency – North West...: Salary TBC

Engagement Expert, Healthcare Brand Communications, London: Excellent package

Engagement Specialist, Healthcare Brand Communications, London, ...: circa £50K

Account Manager / Account Director: Competative

Business Director: Competitive Salary Offered

Senior Account Manager: Competitive Salary Offered

Senior Account Manager, Rare Diseases – Medical Communications, ...: Excellent package

PRINCIPAL MEDICAL WRITER > ETL - LONDON / NEW YORK/ HOME - ME...: Salary TBC

Home-based Senior Project Manager – Independent Med Ed: Salary TBC

Subscribe to our email news alerts

PMHub

Add my company

AMICULUM Limited

AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >220 healthcare communications professionals,...

Latest intelligence

Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?: Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement: Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape: Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....